Cargando…
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases
Advanced therapies have transformed the treatment of inflammatory bowel disease; however, many patients fail to respond, highlighting the need for therapies tailored to the underlying cell and molecular disease drivers. The first-in-class oral molecule ABX464 (obefazimod), which selectively upregula...
Autores principales: | Apolit, Cécile, Campos, Noëlie, Vautrin, Audrey, Begon-Pescia, Christina, Lapasset, Laure, Scherrer, Didier, Gineste, Paul, Ehrlich, Hartmut, Garcel, Aude, Santo, Julien, Tazi, Jamal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132720/ https://www.ncbi.nlm.nih.gov/pubmed/36573890 http://dx.doi.org/10.14309/ctg.0000000000000560 |
Ejemplares similares
-
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing
por: Vautrin, Audrey, et al.
Publicado: (2019) -
RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation
por: Manchon, Laurent, et al.
Publicado: (2017) -
The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages
por: Chebli, Karim, et al.
Publicado: (2017) -
Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis
por: Campos, Noëlie, et al.
Publicado: (2015) -
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study
por: Daien, Claire, et al.
Publicado: (2022)